✦ LIBER ✦

9011 NGR-hTNF, a vascular targeting agent (VTA), in previously treated patients with malignant pleural mesothelioma (MPM): a phase II study

✍ Scribed by Gregorc, V.; Ceresoli, G.L.; Zucali, P.A.; De Braud, F.G.; Bajetta, E.; Santoro, A.; Viganò, M.G.; Cappio, F. Caligaris; Lambiase, A.; Bordignon, C.

Book ID: 122003660
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 51 KB
Volume: 7
Category: Article
ISSN: 1359-6349
DOI: 10.1016/S1359-6349(09)71724-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

6617 Phase II study of NGR-hTNF, a selec

6617 Phase II study of NGR-hTNF, a selective vascular targeting agent (VTA), in previously treated patients (pts) with advanced hepatocellular carcinoma (HCC)

✍ Santoro, A.; Citterio, G.; Pressiani, T.; Gregorc, V.; Rimassa, L.; De Braud, F. 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 50 KB

6062 NGR-hTNF, a vascular targeting agen

6062 NGR-hTNF, a vascular targeting agent (VTA), administered as single agent in patients (pts) with colorectal cancer (CRC) failing standard regimens: a phase II study

✍ Rimassa, L.; Santoro, A.; Sobrero, A.F.; Sclafani, F.; Gregorc, V.; Andretta, V. 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 48 KB

1228 Phase I study of NGR-hTNF, a vascul

1228 Phase I study of NGR-hTNF, a vascular targeting agent (VTA), in combination withcisplatin in refractory patients (pts) with solid tumours

✍ G. Citterio; F.G. De Braud; V. Gregorc; T.M. De Pas; C. Noberasco; S. Boselli; M 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 51 KB

Activity and safety of NGR-hTNF, a selec

Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma

✍ Santoro, A; Pressiani, T; Citterio, G; Rossoni, G; Donadoni, G; Pozzi, F; Rimass 📂 Article 📅 2010 🏛 Nature Publishing Group 🌐 English ⚖ 513 KB

6066 Phase II study of two doses of NGR-

6066 Phase II study of two doses of NGR-hTNF, a vascular targeting agent (VTA), combined with capecitabine/oxaliplatin (XELOX) in colorectal cancer (CRC) patients failing standard regimens

✍ Sobrero, A.F.; Pessino, A.; Andretta, V.; Bennicelli, E.; Fornarini, G.; Caprion 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 48 KB

Phase II study of NGR-hTNF, a selective

Phase II study of NGR-hTNF, a selective vascular targeting agent, in patients with metastatic colorectal cancer after failure of standard therapy

✍ Armando Santoro; Lorenza Rimassa; Alberto F. Sobrero; Giovanni Citterio; Frances 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 206 KB